Neoadjuvant cisplatin-based chemotherapy in nonmetastatic muscle-invasive bladder cancer: A systematic review and pooled meta-analysis to determine the preferred regimen To determine whether neoadjuvant gemcitabine and cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) before radical cystectomy improves overall survival (OS), progression-free survival (PFS), and pathologic complete response (pCR) for patients with muscle-invasive bladder cancer (MIBC) with secondary analyses of pathological downstaging and toxicity.
https://www.goldjournal.net/ar....ticle/S0090-4295(24)